MARKET

JAZZ

JAZZ

Jazz Phrmt
NASDAQ

Real-time Quotes | Nasdaq Last Sale

165.75
-3.05
-1.81%
Closed 17:13 03/02 EST
OPEN
168.89
PREV CLOSE
168.80
HIGH
168.89
LOW
164.70
VOLUME
567.24K
TURNOVER
--
52 WEEK HIGH
178.64
52 WEEK LOW
86.88
MARKET CAP
9.34B
P/E (TTM)
39.43
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
PAO Group Inc.’s CBD-Based Nutraceutical Shows Promise In Treating COPD… And Could Create Massive Shareholder Value
Mar 02, 2021 (AB Digital via COMTEX) -- Don't let PAO Group, Inc.'s (USOTC: PAOG) stock price fool you. PAOG should be worth far more than its sub-penny...
ABNewswire · 20h ago
DJ Jazz Pharmaceuticals Is Maintained at Buy by UBS
Dow Jones · 1d ago
DJ Jazz Pharmaceuticals Price Target Raised to $228.00/Share From $174.00 by UBS
Dow Jones · 1d ago
UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $228
UBS analyst Esther Rajavelu maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $174 to $228.
Benzinga · 1d ago
--Analyst Actions: UBS Adjusts PT on Jazz Pharmaceuticals to $228 From $174 on 2021 Guidance, GW Pharmaceuticals Deal; Buy Rating Kept
MT Newswires · 1d ago
GW Pharma get European nod on expanded label for Epidyolex
GW Pharmaceuticals (GWPH) announced that the European Medicines Agency has issued a positive opinion on its Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated
Seekingalpha · 4d ago
Item 9 Labs and Why Franchising is the Growth Vehicle to Propel the Cannabis Industry
Item 9 Labs Corp. is a sponsor and will speak at the Benzinga Cannabis Capital Conference set to take place on February 25-26, 2021.
Benzinga · 4d ago
Global Gene Therapy Market: Comprehensive Study, Application, Top Companies , Regional Insights and COVID-19 Impact Analysis
Feb 26, 2021 (Heraldkeepers) -- Global Gene Therapy Market is valued at USD 1.5 billion in 2020 which is expected to reach USD 6.8 billion by 2027 at a CAGR...
Heraldkeepers · 4d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of JAZZ. Analyze the recent business situations of Jazz Phrmt through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average JAZZ stock price target is 198.00 with a high estimate of 235.00 and a low estimate of 162.00.
EPS
Institutional Holdings
Institutions: 703
Institutional Holdings: 58.49M
% Owned: 103.84%
Shares Outstanding: 56.33M
TypeInstitutionsShares
Increased
127
2.49M
New
106
206.41K
Decreased
167
4.55M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.38%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Chairman/Chief Executive Officer/Director
Bruce Cozadd
President/Chief Operating Officer
Daniel Swisher
Chief Financial Officer/Executive Vice President
Renee Gala
Executive Vice President/General Manager
Kimberly Sablich
Executive Vice President
Robert Iannone
Senior Vice President/General Counsel
Neena Patil
Senior Vice President
Finbar Larkin
Senior Vice President
Samantha Pearce
Chief Accounting Officer/Vice President
Patricia Carr
Director
Jennifer Cook
Director
Mark Smith
Independent Director
Paul Berns
Independent Director
Patrick Enright
Independent Director
Peter Gray
Independent Director
Heather McSharry
Independent Director
Heather Mcsharry
Independent Director
Seamus Mulligan
Independent Director
Kenneth O'Keefe
Independent Director
Anne O'Riordan
Independent Director
Norbert Riedel
Independent Director
Elmar Schnee
Independent Director
Catherine Sohn
Independent Director
Rick Winningham
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About JAZZ
Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.

Webull offers kinds of Jazz Pharmaceuticals PLC stock information, including NASDAQ:JAZZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAZZ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JAZZ stock methods without spending real money on the virtual paper trading platform.